Overview of Trimethobenzamide
Trimethobenzamide, commonly known by the brand name Tigan, is an antiemetic medication used to treat postoperative nausea and vomiting, as well as nausea associated with gastroenteritis. It belongs to the anticholinergic antiemetics drug class and works by potentially involving the chemoreceptor trigger zone (CTZ) in the medulla oblongata[1].
Market Size and Growth
The global antiemetics drugs market, which includes trimethobenzamide, was valued at USD 7.49 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.98% from 2024 to 2030, reaching USD 11.20 billion by 2030. This growth is driven by rising incidences of gastroenteritis and cancer, as well as increasing research and development activities in the field[3].
Regional Market Dynamics
North America dominated the antiemetics drugs market in 2023, with a share of 36.52%, largely due to the presence of key players such as Pfizer and GSK plc. The Asia Pacific region is also expected to grow significantly, driven by increasing cases of cancer and gastroenteritis, and the growing availability of various antiemetic medications[3].
Pricing and Availability
The cost of trimethobenzamide can vary depending on the formulation and the pharmacy. For instance, the cost for a 30-day supply of 300 mg oral capsules can range from $25 to $61.44, depending on the quantity purchased. The use of discount cards can further reduce the cost by up to 80%[2].
Recent Developments and Supply Chain
Pfizer discontinued the production of oral Tigan (trimethobenzamide) in 2021, leading to a shortage that was expected to be depleted by May 2021. However, Chartwell launched its own trimethobenzamide capsules in late 2023, addressing the supply gap. This transition highlights the dynamic nature of the pharmaceutical market and the importance of multiple manufacturers to ensure continuous supply[4].
Patient Assistance and Copay Programs
While there are no specific patient assistance programs (PAPs) or copay programs available for trimethobenzamide, patients may benefit from general discount cards and other cost-saving initiatives. Healthcare providers can also offer guidance on available programs in their area[2].
Competitive Landscape
The antiemetics drugs market is competitive, with several key players including Pfizer Inc., Cipla Inc., Merck & Co., Inc., and GSK plc. The market is also influenced by the launch of generic substitutes, which can impact pricing and market share[3].
Future Projections
Given the growing demand for antiemetic medications due to increasing cases of cancer and gastroenteritis, the market for trimethobenzamide is expected to remain robust. Here are some key projections:
- Market Growth: The global antiemetics drugs market is expected to grow at a CAGR of 5.98% from 2024 to 2030.
- Regional Expansion: The Asia Pacific region is anticipated to show significant growth due to rising health issues and increasing availability of antiemetic medications.
- Pricing Trends: Prices may stabilize or decrease slightly with the introduction of generic alternatives and competitive market dynamics.
- Supply Chain: The recent entry of Chartwell into the market is expected to stabilize the supply of trimethobenzamide, reducing the risk of future shortages[3][4].
Key Takeaways
- Trimethobenzamide is a crucial antiemetic medication with a growing market demand.
- The global antiemetics drugs market is projected to reach USD 11.20 billion by 2030.
- Regional growth, especially in the Asia Pacific, will be significant due to health trends and market availability.
- Pricing will be influenced by discount programs, generic alternatives, and competitive market dynamics.
- Supply chain stability has been enhanced with the entry of new manufacturers like Chartwell.
FAQs
1. What is the primary use of trimethobenzamide?
Trimethobenzamide is primarily used to treat postoperative nausea and vomiting, as well as nausea associated with gastroenteritis[1].
2. How is the global antiemetics drugs market expected to grow?
The global antiemetics drugs market is expected to grow at a CAGR of 5.98% from 2024 to 2030, reaching USD 11.20 billion by 2030[3].
3. What factors are driving the growth of the antiemetics drugs market?
The growth is driven by rising incidences of gastroenteritis and cancer, as well as increasing research and development activities in the field[3].
4. What happened to the supply of trimethobenzamide in 2021?
Pfizer discontinued the production of oral Tigan (trimethobenzamide) in 2021, leading to a shortage. However, Chartwell launched its own trimethobenzamide capsules in late 2023 to address the supply gap[4].
5. Are there any patient assistance programs available for trimethobenzamide?
There are no specific patient assistance programs (PAPs) or copay programs available for trimethobenzamide, but general discount cards and other cost-saving initiatives can help reduce costs[2].
Sources
- DrugBank: Trimethobenzamide: Uses, Interactions, Mechanism of Action.
- Drugs.com: Trimethobenzamide Prices, Coupons, Copay Cards & Patient Assistance.
- Grand View Research: Antiemetics Drugs Market Size & Share Analysis Report 2030.
- ASHP: Drug Shortage Detail: Trimethobenzamide Capsules.
- Business Research Insights: Nausea and Vomiting Treatment Market Size - Forecast 2032.
